Zhitong Finance App News, Xinhua Pharmaceutical (000756.SZ) issued an announcement. Recently, the company received the “Drug Registration Certificate” for oseltamivir phosphate suspension (hereinafter referred to as “this product”) approved and issued by the State Drug Administration. This product is used to treat influenza A and B in patients aged 2 weeks and above (oseltamivir phosphate can effectively treat influenza A and B, but there is not much clinical application data for influenza B). Patients should use it within 48 hours of first onset of symptoms. This product can also be used to prevent influenza A and B in people aged 1 year and over.

Zhitong Finance App News, Xinhua Pharmaceutical (000756.SZ) issued an announcement. Recently, the company received the “Drug Registration Certificate” for oseltamivir phosphate suspension (hereinafter referred to as “this product”) approved and issued by the State Drug Administration. This product is used to treat influenza A and B in patients aged 2 weeks and above (oseltamivir phosphate can effectively treat influenza A and B, but there is not much clinical application data for influenza B). Patients should use it within 48 hours of first onset of symptoms. This product can also be used to prevent influenza A and B in people aged 1 year and over.